Edgewise Therapeutics (EWTX) revenue
There is no revenue history on record here for Edgewise Therapeutics (EWTX). Figures as of 18 Nov 2026, 09:52 UTC, from the company's filings with the SEC and Yahoo Finance.
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Not enough data
A history of revenue needs at least 3 fiscal years; none is on record here for Edgewise Therapeutics. Nothing is estimated to fill the gap.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Revenue at health care companies of similar size
| Company | Revenue | Fiscal year |
|---|---|---|
| Concentra Group Holdings Parent CON | $2.16B | 2025 |
| Merit Medical Systems MMSI | $1.52B | 2025 |
| LivaNova LIVN | $1.39B | 2025 |
| Ionis Pharmaceuticals IONS | $943.71M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Edgewise Therapeutics, figure by figure
- Edgewise Therapeutics market cap
- Edgewise Therapeutics earnings
- Edgewise Therapeutics earnings per share (EPS)
- Edgewise Therapeutics P/E ratio
- Edgewise Therapeutics P/S ratio
- Edgewise Therapeutics P/B ratio
- Edgewise Therapeutics free cash flow
- Edgewise Therapeutics operating margin
- Edgewise Therapeutics dividend
- Edgewise Therapeutics shares outstanding
- Edgewise Therapeutics total debt
- Edgewise Therapeutics cash on hand
- Edgewise Therapeutics total assets
- Edgewise Therapeutics return on equity (ROE)
- Edgewise Therapeutics return on invested capital (ROIC)
Edgewise Therapeutics (EWTX) overview: price, valuation and scorecardAll health care companies by market value
Edgewise Therapeutics revenue: questions and answers
How is Edgewise Therapeutics's revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Edgewise Therapeutics (EWTX) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/EWTX/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.